A randomized double-blind study of acetohydroxamic acid in struvite nephrolithiasis

Area of Science:

• Nephrology
• Urology
• Infectious Diseases

Background:

• Struvite stones are associated with urinary tract infections caused by urea-splitting bacteria.
• Bacterial urease activity contributes to struvite stone formation and growth.
• Acetohydroxamic acid is a bacterial urease inhibitor with potential therapeutic applications.

Purpose of the Study:

• To evaluate the efficacy of acetohydroxamic acid in inhibiting the growth of struvite stones.
• To assess the safety and adverse effects associated with acetohydroxamic acid treatment.
• To compare acetohydroxamic acid therapy with placebo in a randomized double-blind study.

Main Methods:

• A randomized double-blind study comparing acetohydroxamic acid (15 mg/kg/day) with placebo.
• Participants included patients with struvite stones and urea-splitting bacterial infections.
• Study duration averaged 15.8 months for acetohydroxamic acid and 19.6 months for placebo.

Main Results:

• No patient receiving acetohydroxamic acid experienced a doubling of stone size, unlike 7 placebo recipients (P < 0.01).
• Adverse effects led to dose reduction or cessation in 9 acetohydroxamic acid patients versus 1 placebo patient (P < 0.01).
• Tremulousness and phlebothrombosis were observed in the acetohydroxamic acid group.

Conclusions:

• Acetohydroxamic acid demonstrates short-term efficacy in inhibiting struvite stone growth in infected patients.
• High prevalence of adverse reactions necessitates careful consideration for long-term therapy.
• Long-term toxicity and effectiveness for struvite nephrolithiasis require further definition.